MetaCap

Arcturus Therapeutics (ARCT) vs Enanta Pharmaceuticals (ENTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcturus Therapeutics (ARCT) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 19.0% versus a loss of 40.1%. Over five years, ARCT leads with a -81.3% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $214.7 million), about 1.0 times the size.

Arcturus Therapeutics converts more of its revenue into profit, with a net margin of -80.2% versus -108.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARCT+19.01%ENTA-40.14%
+181%+65%-51%
Nov 21, 20251 yearNov 20, 2026
ARCT-79.56%ENTA-89.88%
+35%-32%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARCT versus ENTA key metrics
MetricARCTENTA
Share price$7.45$7.62
Market cap$214.73M$222.19M
1-day change-1.97%-4.51%
YTD return+21.53%-51.68%
1-year return+19.01%-40.14%
5-year return-81.32%-91.71%
EPS (TTM)$-3.10$-2.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$82.03M$63.00M
Revenue growth (YoY)-46.14%-3.56%
Net income (latest FY)$-65.78M$-68.25M
Operating margin-92.96%-99.01%
Net margin-80.19%-108.33%
52-week high$17.96$17.15
52-week low$5.50$7.56
Distance from 52-week high-58.52%-55.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+218.12%+186.48%
Average volume851.45K287.81K
Shares outstanding28.82M29.16M
Employees106120
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARCT has outperformed ENTA by 59.2 percentage points over the past year.
  • Arcturus Therapeutics is more profitable, keeping -80.2 cents of every revenue dollar as net income versus -108.3 cents for Enanta Pharmaceuticals.
  • Enanta Pharmaceuticals grew revenue faster in its latest fiscal year (-3.56% vs -46.14%).

About Arcturus Therapeutics

ARCT stock →

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

ARCT vs ENTA FAQ

Which is bigger, Arcturus Therapeutics or Enanta Pharmaceuticals?

Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $214.73M for Arcturus Therapeutics (ARCT).

Which stock has performed better over the past year, ARCT or ENTA?

ARCT returned +19.01% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.

Are Arcturus Therapeutics and Enanta Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons